Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission ...
Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company headquartered in Austin, Texas, focused on developing potentially transformative treatments for patients with cancer and diabetes. The company’s mission centers on advancing gene-based medicines through clinical development toward regulatory approval and commercialization. At the core of Genprex’s pipeline is REQORSA ...Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company headquartered in Austin, Texas, focused on developing potentially transformative treatments for patients with cancer and diabetes. The company’s mission centers on advancing gene-based medicines through clinical development toward regulatory approval and commercialization.
At the core of Genprex’s pipeline is REQORSA (GPX-001), its flagship gene therapy candidate designed to target both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The company also advances GPX-002, another gene therapy program aimed at treating diabetes, which is currently in the preclinical stage. As with many early-stage gene-therapy developers, progress depends heavily on generating clinical evidence (e.g., safety, tolerability, and efficacy signals), navigating regulatory requirements, and scaling manufacturing and quality systems to support clinical supply.
From a business perspective, Genprex’s activities typically involve significant R&D investment relative to revenue, since therapeutic candidates generally require years of laboratory work, preclinical studies, and multiple clinical trial phases before commercialization. Cost structures often emphasize program-specific development expenses such as clinical operations, regulatory strategy, data management, and manufacturing/CMC (chemistry, manufacturing, and controls). While detailed bill-of-materials (BOM) or unit production costs are not usually disclosed in public summaries for gene therapies, key cost drivers commonly include vector/material sourcing, fill-finish and drug product preparation, testing for quality attributes, and maintaining compliant production processes.
Financially, clinical-stage biotechnology companies like Genprex often prioritize cash preservation and milestone-driven funding because revenue may be limited or non-existent until late-stage trials and commercialization occur. The company’s balance sheet and valuation metrics can therefore fluctuate with trial outcomes, financing conditions, and progress through development stages.
Leadership and governance are anchored by Ryan M. Confer, who serves as President and Chief Executive Officer (and also CFO per the provided board listing). Genprex was founded in 2009 (initially associated with co-founders including Rodney Varner and David Nance), and it has since built a focused pipeline around oncology and metabolic disease.
Looking ahead, Genprex’s “wishes” from an investor and stakeholder perspective typically align with (1) advancing REQORSA through meaningful clinical readouts, (2) sustaining or expanding program momentum toward additional indications or supportive data, (3) translating preclinical GPX-002 progress into productive clinical development, and (4) securing sufficient financing to continue development and operational readiness as milestones approach.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-16.2M
+23.1%
+0.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-15.3M
+10.7%
-63.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.0%
—
—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
3.84x
+363.2%
+20.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
